STOCKHOLM, March 31, 2025 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi®) published its Annual and sustainability report today. The report details the progress Sobi has made in 2024 ...

STOCKHOLM, March 31, 2025 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi®) published its Annual and sustainability report today. The report details the progress Sobi has made in 2024 ...

Ionis Pharmaceuticals (NASDAQ:IONS) has entered into a license agreement under which Sobi receives exclusive rights in countries outside the U.S., Canada and China to commercialize olezarsen as a ...

Sobi will be responsible for future regulatory submissions and commercialization in ex-U.S. geographies except Canada and China. Olezarsen was licensed to Theratechnologies for commercialization ...

Sobi has completed the acquisition of AstraZeneca’s Synagis (palivizumab) for $1.5 billion in cash and shares, plus certain conditional payments. As part of the deal, first announced in August ...

Sweden’s Sobi has kicked off a rolling biologics license application in the US for SEL-212, vying to become a new option for patients with refractory chronic gout that doesn’t respond to ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...